Fundz

Qihan Biotech Raises Additional Usd 67 Million In Series A++ Financing

PRIVATEMar 29, 2021

Amount Raised

$67 Million

Round Type

Series A

HangzhouBiotechnologyHealth CareMedicalTherapeutics

Description

Qihan Biotechnology Co. Ltd ( or ), a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ financing. Proceeds from the financing will primarily be used to advance Qihan’s pipeline of novel cell therapies in IND-enabling studies and hypoimmunity projects, and expansion of the company’s GMP manufacturing facilities.

Quick answer

Qihan Biotech raised $67 Million in a Series A round, dated March 29, 2021. Qihan Biotech is based in Hangzhou, Zhejiang, China.

How much did Qihan Biotech raise?
Qihan Biotech raised $67 Million in a Series A round on March 29, 2021.
What does Qihan Biotech do?
Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation.
Where is Qihan Biotech based and how big is it?
Qihan Biotech is based in Hangzhou, Zhejiang, China.
Who are the decision-makers at Qihan Biotech?
Fundz holds 1 contact at Qihan Biotech. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Qihan Biotech that raised within 45 days of this round, from Fundz verified event records.

  • Immunome Inc. raised $27M on May 11, 2021.
  • Scipher Medicine raised $82M on March 26, 2021.
  • Century Therapeutics, Inc. raised an undisclosed amount on March 15, 2021.
  • Acrivon Therapeutics raised $16M on February 12, 2021.
  • Eikon Therapeutics raised $103M on May 13, 2021.
  • Nuvalent raised $135M on May 12, 2021.

Who to call at Qihan Biotech, and when

A new round usually means Qihan Biotech is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Qihan Biotech raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Qihan Biotech, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Qihan Biotech. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Qihan Biotech

Location

Hangzhou, Zhejiang, China

About

Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation. The company’s mission is to use high-throughput, multiplexable genome editing in combination with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other important medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised three rounds of financing and is advancing its cell therapy programs into IND-enabling investigations.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Qihan Biotech raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Qihan Biotech's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Qihan Biotech raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.